Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary UNITE® platform, designed to utilize the body’s natural biochemistry to develop broad immune responses. The company focuses on applying the UNITE® platform to oncology, animal health, infectious disease, and allergy, aiming to develop immune-based therapies that improve health and extend lives of patients.
Industries
Nr. of Employees
small (1-50)
Immunomic Therapeutics, Inc.
Patents
Products
Plasmid DNA therapeutic vaccine for glioblastoma (early‑phase)
A plasmid DNA vaccine designed to target virus‑associated antigens expressed in glioblastoma; advanced into a Phase I clinical trial.
Self‑amplifying RNA vaccine candidates (preclinical)
saRNA vaccine constructs under preclinical development for oncology indications including virus‑associated cancers and triple negative breast cancer, and for allergy indications.
Monoclonal antibody immune‑modulator (preclinical)
A monoclonal antibody candidate designed to block a receptor involved in regulatory T cell signaling as a next‑generation checkpoint approach; in preclinical development.
Plasmid DNA therapeutic vaccine for glioblastoma (early‑phase)
A plasmid DNA vaccine designed to target virus‑associated antigens expressed in glioblastoma; advanced into a Phase I clinical trial.
Self‑amplifying RNA vaccine candidates (preclinical)
saRNA vaccine constructs under preclinical development for oncology indications including virus‑associated cancers and triple negative breast cancer, and for allergy indications.
Monoclonal antibody immune‑modulator (preclinical)
A monoclonal antibody candidate designed to block a receptor involved in regulatory T cell signaling as a next‑generation checkpoint approach; in preclinical development.
Expertise Areas
- Nucleic acid vaccine development
- Oncology immunotherapy
- Preclinical immunology and tumor models
- Early‑phase clinical trial management
Key Technologies
- Nucleic acid vaccines
- Plasmid DNA (pDNA) constructs
- Self-amplifying RNA (saRNA)
- Lysosomal targeting for antigen presentation
News & Updates
Immunomic Therapeutics is proud to be a bronze sponsor for The Alliance for mRNA Medicines (AMM) 1st Annual Meeting. The event will bring together senior executives and top decision-makers in the mRNA industry.
Immunomic Therapeutics announced a presentation on Self-amplifying RNA vaccines using the UNITE® platform for Triple-negative Breast Cancer at SITC 39th Annual Meeting 2024.
Immunomic Therapeutics reports positive results from its Phase 1 clinical trial of ITI-3000 in patients diagnosed with Merkel Cell Carcinoma, demonstrating a favorable safety and tolerability profile.
Immunomic Therapeutics' article on LAMP1 targeting of the large T antigen of Merkel cell polyomavirus, published in Frontiers in Immunotherapy, showing potent CD4 T cell responses and tumor inhibition.
An article discussing the LAMP1 targeting of the large T antigen of Merkel cell polyomavirus, eliciting potent CD4+ T cell responses and tumor inhibition.
Immunomic Therapeutics is proud to be a bronze sponsor for The Alliance for mRNA Medicines (AMM) 1st Annual Meeting. The event will bring together senior executives and top decision-makers in the mRNA industry.
Immunomic Therapeutics announced a presentation on Self-amplifying RNA vaccines using the UNITE® platform for Triple-negative Breast Cancer at SITC 39th Annual Meeting 2024.
Immunomic Therapeutics reports positive results from its Phase 1 clinical trial of ITI-3000 in patients diagnosed with Merkel Cell Carcinoma, demonstrating a favorable safety and tolerability profile.
Immunomic Therapeutics' article on LAMP1 targeting of the large T antigen of Merkel cell polyomavirus, published in Frontiers in Immunotherapy, showing potent CD4 T cell responses and tumor inhibition.
An article discussing the LAMP1 targeting of the large T antigen of Merkel cell polyomavirus, eliciting potent CD4+ T cell responses and tumor inhibition.